Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

Kanako Bokuda, Atsuhiro Ichihara, Mariyo Sakoda, Asako Mito, Kenichiro Kinouchi, Hiroshi Itoh

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Angiotensin receptor blockers (ARBs) are known to reduce the cardiovascular risk in hypertensive patients. This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS). A total of 53 consecutive hypertensive patients with MetS were randomly assigned to the candesartan group, in which candesartan was added on, or the CCBs group, in which CCBs were added on. Clinical and biological parameters were obtained before and after the 12-month treatment period. The primary measure of efficacy was the %change in CAVI. When treated with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11%. Blood pressure (BP) significantly decreased with both treatments, but the differences between groups were not significant. The changes in other parameters remained unchanged in both the groups. Analysis of covariance found that both the BP reduction and the therapy difference contributed to the decrease in CAVI, but the BP reduction was not involved in the decrease in CAVI caused by the difference in the therapy. Candesartan may be a better antihypertensive drug than CCBs to improve subclinical atherosclerosis of patients with MetS.

Original languageEnglish
Pages (from-to)571-578
Number of pages8
JournalVascular Health and Risk Management
Volume6
Issue number1
Publication statusPublished - 2010

Fingerprint

Calcium Channel Blockers
Ankle
Blood Vessels
Blood Pressure
Angiotensin Receptor Antagonists
Atherosclerosis
Therapeutics
Antihypertensive Agents
candesartan

Keywords

  • Albuminuria
  • Ambulatory blood pressure
  • Calcium channel blockers
  • Carotid intima-media thickness

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. / Bokuda, Kanako; Ichihara, Atsuhiro; Sakoda, Mariyo; Mito, Asako; Kinouchi, Kenichiro; Itoh, Hiroshi.

In: Vascular Health and Risk Management, Vol. 6, No. 1, 2010, p. 571-578.

Research output: Contribution to journalArticle

Bokuda, Kanako ; Ichihara, Atsuhiro ; Sakoda, Mariyo ; Mito, Asako ; Kinouchi, Kenichiro ; Itoh, Hiroshi. / Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. In: Vascular Health and Risk Management. 2010 ; Vol. 6, No. 1. pp. 571-578.
@article{30d0c8616ea24e7fab5a9faa743cce6d,
title = "Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome",
abstract = "Angiotensin receptor blockers (ARBs) are known to reduce the cardiovascular risk in hypertensive patients. This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS). A total of 53 consecutive hypertensive patients with MetS were randomly assigned to the candesartan group, in which candesartan was added on, or the CCBs group, in which CCBs were added on. Clinical and biological parameters were obtained before and after the 12-month treatment period. The primary measure of efficacy was the {\%}change in CAVI. When treated with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11{\%}. Blood pressure (BP) significantly decreased with both treatments, but the differences between groups were not significant. The changes in other parameters remained unchanged in both the groups. Analysis of covariance found that both the BP reduction and the therapy difference contributed to the decrease in CAVI, but the BP reduction was not involved in the decrease in CAVI caused by the difference in the therapy. Candesartan may be a better antihypertensive drug than CCBs to improve subclinical atherosclerosis of patients with MetS.",
keywords = "Albuminuria, Ambulatory blood pressure, Calcium channel blockers, Carotid intima-media thickness",
author = "Kanako Bokuda and Atsuhiro Ichihara and Mariyo Sakoda and Asako Mito and Kenichiro Kinouchi and Hiroshi Itoh",
year = "2010",
language = "English",
volume = "6",
pages = "571--578",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome

AU - Bokuda, Kanako

AU - Ichihara, Atsuhiro

AU - Sakoda, Mariyo

AU - Mito, Asako

AU - Kinouchi, Kenichiro

AU - Itoh, Hiroshi

PY - 2010

Y1 - 2010

N2 - Angiotensin receptor blockers (ARBs) are known to reduce the cardiovascular risk in hypertensive patients. This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS). A total of 53 consecutive hypertensive patients with MetS were randomly assigned to the candesartan group, in which candesartan was added on, or the CCBs group, in which CCBs were added on. Clinical and biological parameters were obtained before and after the 12-month treatment period. The primary measure of efficacy was the %change in CAVI. When treated with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11%. Blood pressure (BP) significantly decreased with both treatments, but the differences between groups were not significant. The changes in other parameters remained unchanged in both the groups. Analysis of covariance found that both the BP reduction and the therapy difference contributed to the decrease in CAVI, but the BP reduction was not involved in the decrease in CAVI caused by the difference in the therapy. Candesartan may be a better antihypertensive drug than CCBs to improve subclinical atherosclerosis of patients with MetS.

AB - Angiotensin receptor blockers (ARBs) are known to reduce the cardiovascular risk in hypertensive patients. This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS). A total of 53 consecutive hypertensive patients with MetS were randomly assigned to the candesartan group, in which candesartan was added on, or the CCBs group, in which CCBs were added on. Clinical and biological parameters were obtained before and after the 12-month treatment period. The primary measure of efficacy was the %change in CAVI. When treated with candesartan, but not CCBs, CAVI significantly decreased from 8.7 to 7.7 by 11%. Blood pressure (BP) significantly decreased with both treatments, but the differences between groups were not significant. The changes in other parameters remained unchanged in both the groups. Analysis of covariance found that both the BP reduction and the therapy difference contributed to the decrease in CAVI, but the BP reduction was not involved in the decrease in CAVI caused by the difference in the therapy. Candesartan may be a better antihypertensive drug than CCBs to improve subclinical atherosclerosis of patients with MetS.

KW - Albuminuria

KW - Ambulatory blood pressure

KW - Calcium channel blockers

KW - Carotid intima-media thickness

UR - http://www.scopus.com/inward/record.url?scp=79952059220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952059220&partnerID=8YFLogxK

M3 - Article

C2 - 20730073

AN - SCOPUS:79952059220

VL - 6

SP - 571

EP - 578

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -